Abstract 5231
Background
The use of cell based immune therapies involving infusion of autologous T-lymphocytes with anti-tumor activity targeting tumor-associated antigens is a rapidly evolving area of research. One approach involves the use of peripheral blood as a source of lymphocytes that are then used in the generation of cytotoxic tumor-specific T cells via introducing a tumor-specific TCR gene into T lymphocytes. NY-ESO-1 is a cancer testis antigen expressed in numerous cancers yet absent in most adult normal tissues apart from high expression in adult testes – thereby making it an ideal target for immunotherapy.
Trial design
TB1-1301 is a gene-modified T cell product that contains a NY-ESO-1 specific TCR introduced with the MS3II-NY-ESO1-SiTCR retroviral vector. This vector encodes for TCR α and β chains that recognize an NY-ESO-1 derived epitope (amino acids 157-165: SLLMWITQC) that is presented in the context of HLA-A*02:01 and HLA-A*02:06 molecules. The vector also encodes for siRNA (small interfering RNA) that are homologous to the constant region sequence of the endogenous, but not transduced TCR α and β chain mRNAs – these siRNAs in turn increase expression of the transduced TCR. Pre-clinical murine studies demonstrated safety, persistence, and efficacy of transduced T cells. This study represents a Phase 1b study of TBI-1301 in patients with advanced solid tumors, which express NY-ESO-1 (synovial sarcoma, ovarian cancer, and melanoma). A pre-conditioning lymphodepletion regimen of cyclophosphamide 750 mg/m2 will be used on Day -3 and Day -2 prior to infusion of cell product. The objectives of this study include assessing the safety profile of TBI-1301, determining the RP2D dose, and evaluating the efficacy of TBI-1301 via RECIST v1.1.
Clinical trial identification
NCT02869217.
Legal entity responsible for the study
Tumor Immunotherapy Program, Princess Margaret Cancer Centre.
Funding
Takara Bio Inc.
Editorial Acknowledgement
This clinical trial has received funding support from Takara Bio Inc., Japan.
Disclosure
M.O. Butler: Advisory boards: Merck Canada, BMS, Novartis, Immunocore, Immunovaccine, GSK; Research support: Takara Bio Inc. conducting this clinical trial. S. Tanaka: Employee: Takara Bio Inc. N. Hirano: Research support: Takara Bio Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract